
FDA Issues Guidance on Environmental Assessments
The agency provides guidance on determining the need for environmental assessments for gene therapies, vectored vaccines, and viral and microbial products.
FDA has issued a
The guidance includes EA considerations for INDs, BLAs, and BLA supplements for gene therapies and vectored vaccines for infectious disease indications. It also includes EA considerations for INDs, BLAs, and BLA supplements for related viruses and microbes that were generated using recombinant DNA technology. According to the guidance, “EA considerations for INDs, BLAs, and BLA supplements for live attenuated viral or microbial vaccines created by traditional methods, such as serial passaging and recombinant protein-based vaccines,” are not addressed.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.